Prostate Cancer
City of Hope is a nationally recognized leader in the research and treatment of urologic cancers. Your prostate cancer is every bit as unique as you are, and that is why prostate cancer treatment at City of Hope focuses on you and your loved ones.
Prostate cancer is the second most common cancer among men in the United States and the most common cancer in men over 50.
About 1 out of 7 men will be diagnosed with prostate cancer.
Precise prostate cancer tests are crucial for treatment planning. We are equipped with state-of-the-art technologies and specialized staff to ensure an accurate, comprehensive diagnosis of prostate cancer.
Our physicians will personally consult with you about your disease, treatment options and desired outcomes. Afterward, our multidisciplinary team of specialists will work together to discuss, design and deliver an individual treatment plan to meet those goals best.
Our clinicians and researchers collaborate extensively to develop and evaluate new therapies for better survival and quality-of-life outcomes. Patients have access to prostate cancer clinical trials, including new chemotherapy, targeted and hormone therapies, surgical techniques, radiation approaches, and prevention strategies.
When you come to City of Hope, you automatically gain access to an unparalleled array of support services to help you and your loved ones take each step during and after your prostate cancer treatment.
- The most robotic surgery experience in the Western United States
- Leading experts in da Vinci computer-enhanced, minimally invasive surgery
- Now offering outpatient robotic surgery
- Collaboration with precision medicine, such as genetic counseling and genomic testing
- Multidisciplinary care and coordination, including genetic evaluation
- mpMRI and fusion prostate biopsy to enhance tumor detection and personalize treatment plans
- Televideo or in-person appointments scheduled within five to seven days
- A five-year survival rate close to 100% and superior outcomes for Stages 1-4
- Clinical trials that aim to improve prostate cancer outcomes across the spectrum of the disease, from early to late stage
City Of Hope surpasses SEER LA survival rates for prostate cancer at all stages — every year, we successfully treat thousands of prostate cancer patients. We're proud to announce that our five-year survival rate is very close to 100%.
Our developments in the areas of breakthrough cancer drugs, bone marrow transplants and CAR T cell therapy are recognized internationally.
Our leadership in research and innovation continually enhances our ability to provide novel and differentiated approaches to cancer care.
Kevin Chan, M.D., is a urologic surgeon specializing in bladder cancer and surgical treatment of male urinary incontinence.
Seth Cohen, M.D., is a urologic surgeon with a focus on female pelvic medicine and reconstructive surgery at City of Hope's community practice sites in Glendora and Pasadena..
Tanya Dorff, M.D., is a medical oncologist and an associate professor in the Department of Medical Oncology & Therapeutics Research.
Donald Hannoun, M.D., is a surgeon practicing urology and urologic oncology at City of Hope | Antelope Valley and Santa Clarita.
Clayton Lau, M.D. is chief, Division of Urology and Urologic Oncology, and an expert in prostate cancer.
Diana Londoño, M.D., is a urologic oncology surgeon in the Department of Surgery.
Emmanuel Mitsinikos, M.D., is a surgeon and assistant clinical professor in the Department of Surgery, Division of Urology and Urologic Oncology at City of Hope Upland.
Philip G. Pearson, M.D., is a urologic surgeon at City of Hope's community practice site in Pasadena, California.
Roger Satterthwaite, M.D., is a urologic surgeon specializing in surgery for prostate, kidney, bladder and testicular cancers.
Kristina Wittig M.D., is a urologic surgeon at City of Hope | Antelope Valley in California
